NCT01753713View on ClinicalTrials.gov

Dovitinib in Treating Patients With Recurrent or Progressive Glioblastoma

PHASE2CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

December 20, 2012

Primary Completion Date

January 28, 2015

Study Completion Date

September 20, 2017

Conditions
Adult Giant Cell GlioblastomaAdult GlioblastomaAdult GliosarcomaRecurrent Adult Brain Tumor
Interventions
DRUG

dovitinib

Given PO

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

44195

Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Novartis

INDUSTRY

lead

Manmeet Ahluwalia, MD

OTHER